UN NUEVO AMANECER
en la intercepción temprana de la enfermedad
Destacado


The Straits Times – Netball Singapore (NS) has received a boost ahead of a busy year for the national team, with local biotechnology company MiRXES coming on board as title sponsor of the 2023 and 2024 Nations Cup.
Photo by Lim Yaohui with The Straits Times


MiRXES signed a Memorandum of Understanding with PT ELION MEDIKA INDONESIA (PT ELION) to validate and commercialize MiRXES’s microRNA cancer blood tests for stomach and lung cancers in Indonesia, and establish CADENCE-ID, a joint project for the optimization and validation of a novel multi-cancer blood test, based on blood-borne circulating miRNA and DNA methylation biomarkers in the Indonesian population, for up to nine high incidence and high mortality cancers.
Learn More

MiRXES together with Guest of Honor Dr. Wang Jian, Co-founder and Chairman of BGI Group, unveiled today the cutting-edge DNBSEQ-T10×4RS Genetic Sequencing System (T10), the world’s largest and highest throughput next generation sequencer. The T10 sequencing platform will provide a significant boost to Singapore’s sequencing power and build a high-resolution spatial transcriptomics pipeline in Singapore.
Learn More

MiRXES today launches the first edition of MiRXES Translator Program, Southeast Asia’s first business and clinical advisory program backed by science that bridges post-incubation ideation and post-accelerator growth, at Singapore Week of Innovation and Technology (SWITCH). This program will accelerate revenue growth of start-ups and importantly, adoption of preventive healthcare solutions globally.
Learn More

Singapore-headquartered biotech MiRXES, National University Heart Centre, Singapore (NUHCS) and National Heart Centre Singapore (NHCS) launch SPHERE (Singapore Pulmonary Hypertension Early detection with miRNA biomarkErs) study to identify biomarkers that are relevant to early detection of pulmonary hypertension with the aim to improve Asian patient outcomes and save lives.
Learn More

MiRXES announced today the donation of SG$88,902 to the National University Cancer Institute, Singapore (NCIS) Cancer Fund, a sub-fund of NUHS Fund, at the closing ceremony of Let’s Ride! Singapore today, to assist less fortunate cancer patients with critical cancer treatments. This event was graced by Guest-of-Honor, Ms. Low Yen Ling, Minister of State, Ministry of Trade and Industry & Ministry of Culture, Community and Youth, and Mayor of South West District, who witnessed the cheque presentation ceremony.
Learn More

Prime Minister Lee Hsien Loong spoke about Singapore’s new initiatives to attract and retain top talent to secure Singapore’s success in a post-COVID-19 world. Specific to talent in Singapore’s biomedical sector, PM Lee mentioned that home-grown scientists are now doing cutting-edge research and development, with some who have become principal researchers and others who have founded start-ups.
MiRXES is proud and humbled to be featured in the NDR 2022. We have grown from a three-man team in 2014 to over 360 staff across offices in Singapore, US, China, Japan, and several Southeast Asian countries. We have been a beneficiary of many government initiatives in talent development, technology innovation, internationalization, and scale-up, that have enabled us to develop talent and translate RNA innovation from bench to bedside, and we look forward to continue contributing to Singapore’s vibrant biotechnology ecosystem and Healthier SG initiative.

Nuestra ciencia y forma de desarrollar proyectos
En MiRXES, aprovechamos el poder del ARN para brindar diagnósticos tempranos, procesables y personalizados en todo el proceso de atención para mejorar y salvar vidas. Es mejor prevenir que curar.
Con la detección temprana, la mitigación de los factores de riesgo y la implementación de estrategias de prevención, la mayoría de las muertes por cáncer se pueden prevenir.
Nuestra ciencia nos abre a un mundo sin diagnósticos de cáncer en etapa tardía. Así es como mejoramos y salvamos vidas.
MiRXES se esfuerza por estar a la vanguardia de la detección e interceptación temprana de enfermedades.
Presentamos nuestras soluciones
Actualmente, una de cada cuatro personas tiene cáncer en el mundo. En MiRXES sabemos la importancia de la ciencia en la lucha contra el cáncer.
Entendemos que para lograr el mayor impacto en mejorar y salvar vidas, debemos traducir y entregar nuestras soluciones innovadoras del laboratorio a la clínica.
Obtenga más información sobre cómo nuestras soluciones, que van desde herramientas y servicios de descubrimiento líderes en la industria hasta pruebas de diagnóstico para el cáncer, enfermedades cardiovasculares, metabólicas e infecciosas, y la oncología de precisión, pueden permitirle actuar antes, cuando más importa.

